The current status of NCI trials in Hodgkin’s disease
- 42 Downloads
The development of effective therapies for all stages of Hodgkin’s disease represents one of the most remarkable achievements of modern cancer treatment. What was once considered a uniformly fatal disease has been transformed in the last several decades into one of the most curable malignancies with which we deal. Nevertheless, there are several major areas where improvements in the management of Hodgkin’s disease are needed and several of these areas have been the central focus of ongoing clinical trials at the National Cancer Institute (USA).
KeywordsEarly Stage Disease Complete Remission Rate Luteinizing Hormone Release Hormone Combine Modality Approach Radiat Oncol BioI Phys
Unable to display preview. Download preview PDF.
- 1.Kaplan HS (1970). On the natural history, treatment, and prognosis of Hodgkin’s disease. Harvey Lectures 1968–1969, New York: Academic Press.Google Scholar
- 7.Canellos GP, Young RC and DeVita VT (1972). Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 13: 750–754.Google Scholar
- 10.Pavlovsky S, Dupont J, Jimenez E et al. (1984). Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in Clinical Stage IA-IIA Hodgkin’s disease. In: Cavalli F, Bonadonna G, and Rozencweig M (Eds). Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances, pp 337–343. Boston: Martinus Nijhoff.Google Scholar
- 17.Bonadonna G, Viviani S, Bonfante V et al. (1984). Alternating chemotherapy with MOPP/ABVD in Hodgkin’s disease. Updated results. Proc Amer Soc Clin Oncol 3: 254.Google Scholar